2023 World Conference on Lung Cancer (Posters)-P2.09. Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

P2.09. Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles - PDF(Slides)

Back to course

Pdf Summary

Leptomeningeal metastasis (LM) is a serious complication of advanced non-small cell lung cancer (NSCLC), with a poor prognosis and limited treatment options. Aumolertinib, a novel EGFR tyrosine kinase inhibitor, has shown promise in treating NSCLC patients with brain metastases. This study aims to investigate the efficacy and safety of high-dose aumolertinib combined with intrathecal chemotherapy for LM from EGFR-mutated NSCLC.<br /><br />The study includes NSCLC patients with confirmed EGFR mutations and leptomeningeal metastasis who have received an implanted Ommaya reservoir. The treatment regimen consists of oral aumolertinib and intrathecal chemotherapy with pemetrexed administered via the Ommaya reservoir. The primary endpoint is progression-free survival (PFS), and secondary endpoints include objective response rate (ORR), disease control rate (DCR), duration of response (DoR), overall survival (OS), intracranial PFS (iPFS), intracranial DCR (iDCR), intracranial ORR (iORR), and intracranial DoR (iDoR).<br /><br />The study is currently ongoing, with the first patient enrolled in December 2022. The estimated completion date is in the fourth quarter of 2024. The authors declare no conflicts of interest.<br /><br />In conclusion, this clinical trial aims to assess the effectiveness and safety of high-dose aumolertinib combined with intrathecal chemotherapy for LM in EGFR-mutated NSCLC patients. The study also aims to explore the prognostic value of dynamic changes in cell-free DNA profiles. The results of this trial will provide valuable insights into the optimal treatment strategy for LM and improve outcomes for these patients.

Asset Subtitle

Wei Wang

Meta Tag

Speaker Wei Wang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Leptomeningeal metastasis

non-small cell lung cancer

NSCLC

Aumolertinib

EGFR tyrosine kinase inhibitor

brain metastases

intrathecal chemotherapy

Ommaya reservoir

progression-free survival

objective response rate